Adam Crystal, President, R&D at Tango Therapeutics, Inc. (TNGX), sold 36,904 shares at $12.26 ($453K) on 2026-02-03, disclosed to the SEC on 2026-02-04.
Open-market sale of $453k TNGX by President, R&D. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $12.26 | 18,251 | $224K | 49.4% |
| 2 | $12.26 | 18,251 | $224K | 49.4% |
| 3 | $12.90 | 201 | $3K | 0.6% |
| 4 | $12.90 | 201 | $3K | 0.6% |
| Total | $12.27 avg | 36,904 | $453K | 100% |
| Filing → |
| TNGX | SELL | 2026-08-05 | $736K | — | Filing → |
| TNGX | SELL | 2026-07-02 | $799K | — | Filing → |
| TNGX | SELL | 2026-06-03 | $618K | — | Filing → |